Hangzhou Tigermed Consulting Co., Ltd

Equities

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 14/07/2024 BST			5-day change	1st Jan Change
47.6 ^CNY	-2.06%		-2.86%	-13.41%

07-08	Hangzhou Tigermed Consulting Co., Ltd Announces Implementation of Final Profit Distribution Plan (A Shares) for 2023, Payable on July 12, 2024	CI
07-03	Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024.	CI

Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024.

July 03, 2024 at 08:34 pm

From May 23, 2024 to June 30, 2024, the company has repurchased 3,451,200 shares, representing 0.4% for CNY 184.46 million. With this, the company has completed the repurchase of 3,451,200 shares, representing 0.4% for CNY 184.46 million under the buyback announced on May 24, 2024.

Latest news about Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd Announces Implementation of Final Profit Distribution Plan (A Shares) for 2023, Payable on July 12, 2024	07-08	CI
Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024.	07-03	CI
Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes	06-18	CI
Tigermed Consulting Assures Normal Operations Amid Share Price Fluctuations	06-14	MT
Hangzhou Tigermed Consulting Co., Ltd commences an Equity Buyback Plan for CNY 1,000 million worth of its shares, under the authorization approved on April 30, 2024.	05-23	CI
Hangzhou Tigermed Consulting’s Profit Down 59% in Q1	04-25	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024	04-25	CI
Tigermed Consulting's Profit, Revenue Climb in 2023	03-29	MT
Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year Ended December 31, 2023, Payable on 18 July 2024	03-28	CI
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes	03-21	CI
China Healthcare Stocks Rally on Hopes for Government Support	03-14	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	03-14	RE
Nomura Downgrades Hangzhou Tigermed Consulting to Neutral From Buy, Adjusts Price Target to 49.61 Yuan From 75.72 Yuan	03-05	MT
Nomura Downgrades Tigermed to Neutral From Buy, Adjusts Price Target to HK$32.69 From HK$57.77	03-05	MT
Hangzhou Tigermed Consulting Plans Up to 1 Billion Yuan Share Repurchase; Shares Jump 4%	02-07	MT
Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 1,000 million worth of its shares.	02-06	CI
Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan.	02-05	CI
Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan.	02-05	CI
Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to 75.72 Yuan from 83.50 Yuan, Keeps at Buy	30/10/23	MT
Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to HK$57.77 from HK$64.46, Keeps at Buy	30/10/23	MT
Hangzhou Tigermed Consulting's Profit Up 19% in Q3	27/10/23	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Tigermed Consulting's Profit Jumps 16.5% in H1	28/08/23	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI

Chart Hangzhou Tigermed Consulting Co., Ltd

Duration

Period

Chart Hangzhou Tigermed Consulting Co., Ltd

More charts

Company Profile

Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). China accounts for 46% of sales.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Hangzhou Tigermed Consulting Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

47.6 CNY

Average target price

74.23 CNY

Spread / Average Target

+55.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANGZHOU TIGERMED CONSULTING CO., LTD	-13.41%	5.28B
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.32%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research